Skip to content

An Open-label controlled Trial to Assess the Efficacy of Bisphosphonate in the Treatment of Coronary Artery Calcification in Nondialyzed Patients with Diabetic Nephropathy.

An Open-label controlled Trial to Assess the Efficacy of Bisphosphonate in the Treatment of Coronary Artery Calcification in Nondialyzed Patients with Diabetic Nephropathy. - Effect of Bisphosphonate on Coronary Artery Calcification in Diabetic Nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000250
Enrollment
50
Registered
2006-02-17
Start date
2005-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic nephropathy

Interventions

Oral administration of etidronate No drug that affects coronary artery calcification

Sponsors

Department of Nephrology, Osaka University School of Medicine
Lead Sponsor
Department of Internal Medicine and Therapeutics, Osaka University School of Medicine
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Outpatients in Osaka University hospital with type 2 diabetic nephropathy whose Ccr is equal to or over 30 mL/min according to the estimation of Cockcroft-Gault's formula. Either microalbuminuria (30 mg/dL/Cr or more) or proteinuria is required for the inclusion.

Exclusion criteria

Exclusion criteria: Patients with atrial fibrillation, those who are contraindicated for beta-blockers, pregnant patients, or patients planning pregnancy are excluded.

Design outcomes

Primary

MeasureTime frame
Changes in CACS after 1-year study period.

Secondary

MeasureTime frame
Change in ultrasonographical intima media thickness (IMT) of the carotid artery, brachial ankle pulse wave velocity (baPWV), bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA), and serum concentration of bone turnover markers.

Countries

Japan

Contacts

Public ContactTakahito Ito

Osaka University School of Medicine Department of Nephrology

taka@medone.med.osaka-u.ac.jp06-6879-3632

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026